Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Calls for Maintenance of Current R&D Tax Credit Limit
August 27, 2014
- PFSB’s FY2015 Budget Request Seeks Funding to Increase PMDA Staff by 13 to Strengthen Its Consultation System
August 27, 2014
- MHLW’s FY2015 Budget Request at Record 31.67 Trillion Yen, Includes 74.8 Billion Yen to Promote Commercialization of Innovative New Drugs
August 27, 2014
- PAFSC Second Committee to Review Nobelpharma’s Anticancer Drug Streptozocin on Sept. 5
August 26, 2014
- MHLW to Promote Joint Drug Development by Pharmas, Academia
August 26, 2014
- PAFSC’s First Committee to Discuss Lixiana’s Additional Use on Sept. 4
August 26, 2014
- Editor’s Pick: Five Healthcare News Headlines for August 11 - August 22
August 25, 2014
- PMDA Reviewing Lyrica for Risk of Fulminant Hepatitis, Hepatic Dysfunction
August 25, 2014
- Eisai Sues FDA over Shortened Exclusivity Time for Belviq, Fycompa
August 22, 2014
- MHLW Plans to Build Clinical Trial/Clinical Research Network with Centralized Disease-Based Patient Registry: FY2015 Preliminary Budget Request
August 22, 2014
- Report of Changes to Package Inserts to Be Required Before Providing Revised Information to Healthcare Professionals Under New System
August 21, 2014
- Health Sciences Council to Include “Program to Promote Joint Drug Development by Govt and Private Sector” in FY2015 Budget Request
August 21, 2014
- Generic Use Promotion Best Possible Way for Reducing Social Welfare Expenses: LDP Kono
August 20, 2014
- MHLW Drug Evaluation Head Eyes Flexible Designation Criteria for New Fast-Track Review System
August 19, 2014
- Emergency Use of Favipiravir to Be Permitted if Domestic Outbreak of Ebola Occurs: Health Minister
August 19, 2014
- 148 Blopress Generics OKed, Competition with AGs Likely upon December Listing
August 15, 2014
- MHLW to Lift Ban on Subcontracting of Safety Management Tasks in November
August 15, 2014
- Health Ministry Notifies Prefectures of New Regulatory Service Fees
August 14, 2014
- First Meeting of PMDA’s Panel on Placebo-Controlled Studies Set in Early October
August 13, 2014
- PMDA Will Prosper by Promoting Review Work, Research, and Training Together: Chief Executive
August 13, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…